相关临床试验
49
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
24
49.0%
尚未招募
2
4.1%
招募中
5
10.2%
终止
3
6.1%
Unknown
14
28.6%
撤回
1
2.0%
暂无批准数据
- The fourth edition of the Riyadh Global Medical Biotechnology Summit (RGMBS 2026) will take place from 14 to 16 September 2026 in Saudi Arabia's capital, expecting over 15,000 visitors and delegations from more than 70 countries. - The Summit is organized under Saudi Arabia's National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotechnology by 2040, with six thematic tracks spanning AI, multi-omics, investment, immunology, bioengineering, and workforce development. - More than 100 speakers and over 65 agreements and memoranda of understanding are targeted across the three days, highlighting partnerships with Harvard University, AstraZeneca, and Peking University. - Spain joins Germany, South Korea, China, the United States, and Japan as one of six selected national ecosystems featured in the International Pavilion, with complimentary exhibition space valued at approximately $44,600.
- King Abdullah International Medical Research Center and Flagship Pioneering announced a strategic partnership to conduct early-phase clinical trials of novel genetic disease therapies in Saudi Arabia. - The collaboration will initially focus on three Phase 1 programs and one Phase 2 program from Flagship-founded companies targeting genetic diseases with high unmet medical need. - Saudi investors will commit $70 million to participating U.S.-based companies as part of the partnership framework. - The agreement aims to establish Saudi Arabia as a leader in innovative clinical trials while advancing American biotechnology innovation globally.
